Trevi Therapeutics shifts to late-stage biotech with Haduvio for IPF chronic cough. Click here to read my latest analysis of ...
Trevi Therapeutics, Inc. TRVI shares are trading higher after the company announced the pricing of its $150 million offering ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
There seems to be a strong exposure-response relationship between nerandomilast and the preservation of FVC in patients with PPF and IPF.
In what shakes out to be the largest follow-on stock offering in biopharma history, Revolution Medicines Inc., an oncology company that was the subject of buyout rumors earlier this year, priced 10.56 ...
Peer-reviewed study confirming strong predictive performance of patient-specific lung digital twins, validated against ...
A protein called PIEZO1, which is linked to mechanical stress, may play a key role in driving pulmonary fibrosis, a study ...
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies ...
Cautionary Language Concerning Forward-Looking Statements ...
Regulatory milestone supports broader adoption of C-mo's privacy-preserving technology in clinical research and medical practiceApproval covers the biosensor, automated cough monitoring algorithms and ...
Ebenbuild GmbH, a Munich-based deep-tech healthcare company, today announced the publication of a peer-reviewed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results